Trial Profile
An Open-Label, Multicenter Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Rifampicin (Primary) ; Trabectedin (Primary) ; Dexamethasone
- Indications Malignant melanoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 12 Aug 2011 Actual initiation date changed from Feb 2011 to Dec 2010 and trial phase changed from I/II to I as reported by ClinicalTrials.gov.
- 09 Jun 2011 Planned End Date changed from 1 Apr 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 19 May 2011 Planned end date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.